UY34745A - Vacunas y procedimientos para tratar la enfermedad de lyme en perros - Google Patents

Vacunas y procedimientos para tratar la enfermedad de lyme en perros

Info

Publication number
UY34745A
UY34745A UY0001034745A UY34745A UY34745A UY 34745 A UY34745 A UY 34745A UY 0001034745 A UY0001034745 A UY 0001034745A UY 34745 A UY34745 A UY 34745A UY 34745 A UY34745 A UY 34745A
Authority
UY
Uruguay
Prior art keywords
vaccines
dogs
disease
procedures
immunogenic composition
Prior art date
Application number
UY0001034745A
Other languages
English (en)
Inventor
Robert M Lohse
Jason J Millership
Xu Zach
Patrick F M Meeus
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of UY34745A publication Critical patent/UY34745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una composición inmunógena que comprende un fragmento antigénico de proteína OspA de Borrelia burgdorferi y una proteína quimérica que contiene fragmentos antigénicos de diferentes filotipos de proteína OspC de Borrelia burgdorferi. También se proporcionan vacunas que incorporan la composición inmunógena de la invención, así como procedimientos para prevenir la e nfermedad de Lyme en perros y/o proteger perros de la enfermedad de Lyme usando las vacunas.
UY0001034745A 2012-04-18 2013-04-16 Vacunas y procedimientos para tratar la enfermedad de lyme en perros UY34745A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261635031P 2012-04-18 2012-04-18

Publications (1)

Publication Number Publication Date
UY34745A true UY34745A (es) 2013-11-29

Family

ID=48193279

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034745A UY34745A (es) 2012-04-18 2013-04-16 Vacunas y procedimientos para tratar la enfermedad de lyme en perros

Country Status (10)

Country Link
EP (1) EP2838555A2 (es)
JP (1) JP2015514776A (es)
CN (1) CN104379164A (es)
AR (1) AR090726A1 (es)
AU (1) AU2013249229A1 (es)
BR (1) BR112014025740A2 (es)
CA (1) CA2870179C (es)
EA (1) EA201491668A1 (es)
UY (1) UY34745A (es)
WO (1) WO2013158818A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086057B2 (en) 2014-10-08 2018-10-02 Virginia Commonwealth University Stage specific diagnostic antigens, assay and vaccine for lyme disease
AU2018379121B2 (en) 2017-12-04 2024-05-02 Intervet International B.V. Canine lyme disease vaccine
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
ES2135411T3 (es) * 1991-08-15 1999-11-01 Smithkline Beecham Biolog Proteinas osp a de subgrupos de borrelia burgdorferi, genes codificantes y vacunas.
AU5328299A (en) 1998-07-31 2000-02-21 Gundersen Lutheran Medical Foundation, Inc. Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
EP2283031B1 (en) * 2008-05-02 2017-04-12 Virginia Commonwealth University Lyme disease vaccine
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
US8808705B2 (en) * 2010-10-20 2014-08-19 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen

Also Published As

Publication number Publication date
AU2013249229A1 (en) 2014-10-23
EP2838555A2 (en) 2015-02-25
WO2013158818A2 (en) 2013-10-24
CA2870179C (en) 2018-09-04
CA2870179A1 (en) 2013-10-24
AR090726A1 (es) 2014-12-03
WO2013158818A3 (en) 2014-04-17
EA201491668A1 (ru) 2015-08-31
CN104379164A (zh) 2015-02-25
BR112014025740A2 (pt) 2017-07-04
JP2015514776A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
IL267997A (en) Preparations, formulations and methods for treating eye diseases
CO7160093A2 (es) Anticuerpos anti-egfr y usos de los mismos
BR112012005225B8 (pt) Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
MX2015011199A (es) Agentes terapéuticos de csf1.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CL2014002549A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados.
MX2012013261A (es) Genes ospa quimericos, proteinas, y metodos para usar los mismos.
DOP2013000235A (es) Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.
MX2021004211A (es) Composiciones vacuna.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
ECSP13012893A (es) Ureas asimétricas y usos médicos de las mismas
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
BR112015020079A8 (pt) Composições para cuidado oral
BR112015001843A2 (pt) dispositivo médico, composição de matriz biodegradável e método para tratar um paciente.
CL2015003563A1 (es) Marcador para trastornos de la esfingomielinasa ácida y sus usos.
UY34745A (es) Vacunas y procedimientos para tratar la enfermedad de lyme en perros
WO2014018274A8 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
DK3003363T3 (da) Immunogen sammensætning til anvendelse i terapi
EP2926822A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING A SCEPTRIDIUM JAPONICUM EXTRACT FOR PREVENTING OR TREATING A CEREBRAL VASCULAR ACCIDENT OR DEGENERATIVE BRAIN DISEASES
BR112017004304A2 (pt) composições de pteroestilbeno tópicas para uso em tratamento de perda de função de barreira na pele induzidas por uv
BR112015010675A2 (pt) copolímeros em bloco para a proteção do esmalte do dente
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
MX2014008194A (es) Cefovecina util en el tratamiento de la enfermedad de lyme.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210526